was read the article
array:24 [ "pii" => "S2253808918300740" "issn" => "22538089" "doi" => "10.1016/j.remnie.2018.10.004" "estado" => "S300" "fechaPublicacion" => "2019-03-01" "aid" => "1022" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:87-93" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X1830177X" "issn" => "2253654X" "doi" => "10.1016/j.remn.2018.09.005" "estado" => "S300" "fechaPublicacion" => "2019-03-01" "aid" => "1022" "copyright" => "Sociedad Española de Medicina Nuclear e Imagen Molecular" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:87-93" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 122 "formatos" => array:2 [ "HTML" => 96 "PDF" => 26 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Valor clínico y pronóstico de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG en el cáncer de endometrio recurrente" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "87" "paginaFinal" => "93" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Clinical and prognostic value of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in recurrent endometrial carcinoma" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 638 "Ancho" => 1740 "Tamanyo" => 100760 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Caso representativo de una PET/TC con <span class="elsevierStyleSup">18</span>F-FDG positiva en una mujer de 64<span class="elsevierStyleHsp" style=""></span>años con elevación del CA-125 y un carcinoma endometrioide previamente tratado con cirugía más radioterapia. La proyección de máxima intensidad (MIP; a) muestra la presencia de múltiples focos de captación de FDG. Las imágenes PET y PET/TC axiales muestran lesiones hipermetabólicas en el hígado (b,c), en el hueso que corresponde al esternón y la vértebra (d,e) y en el pulmón izquierdo (f,g).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Albano, V. Zizioli, F. Odicino, R. Giubbini, F. Bertagna" "autores" => array:5 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Albano" ] 1 => array:2 [ "nombre" => "V." "apellidos" => "Zizioli" ] 2 => array:2 [ "nombre" => "F." "apellidos" => "Odicino" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Giubbini" ] 4 => array:2 [ "nombre" => "F." "apellidos" => "Bertagna" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808918300740" "doi" => "10.1016/j.remnie.2018.10.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300740?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X1830177X?idApp=UINPBA00004N" "url" => "/2253654X/0000003800000002/v1_201903020653/S2253654X1830177X/v1_201903020653/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S2253808918300752" "issn" => "22538089" "doi" => "10.1016/j.remnie.2018.10.005" "estado" => "S300" "fechaPublicacion" => "2019-03-01" "aid" => "1021" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:94-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "<span class="elsevierStyleSup">68</span>Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with <span class="elsevierStyleSup">18</span>F-DOPA PET/CT" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "94" "paginaFinal" => "99" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Comparación de PET/TC con <span class="elsevierStyleSup">18</span>F-DOPA y PET/TC con <span class="elsevierStyleSup">68</span>Ga-DOTATOC para la localización de paraganglioma maligno extra-adrenal y feocromocitoma" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1793 "Ancho" => 2084 "Tamanyo" => 190575 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">MIP of <span class="elsevierStyleSup">68</span>Ga-DOTA-TOC PET (A) and <span class="elsevierStyleSup">18</span>F-DOPA PET (B) in a 70 year old male patient suffering from a relapse of metastatic PHEO (patient 8). <span class="elsevierStyleSup">68</span>Ga-DOTA-TOC PET showed a moderate uptake in the thoracic vertebra (C, SUV<span class="elsevierStyleInf">max</span> 4.4), concordant to <span class="elsevierStyleSup">18</span>F-DOPA PET (D, SUV<span class="elsevierStyleInf">max</span> 3.2). After <span class="elsevierStyleSup">68</span>Ga-DOTA-TOC PET/CT fusion a small sclerosis was detected in the 5th thoracic vertebra (E arrow), which was confirmed as osteoblastic metastasis. In addition, a strong focal <span class="elsevierStyleSup">68</span>Ga-DOTA-TOC uptake was found in the left arm (A and F SUV<span class="elsevierStyleInf">max</span> 7.9) – with mild to moderate <span class="elsevierStyleSup">18</span>F-DOPA uptake behaviour in this area (B and G SUV<span class="elsevierStyleInf">max</span> 5.6). Diagnostic CT was not able to clearly differentiate between postoperative changes and tumour residuum after resection of a bone metastasis five years ago in the left arm (H). After fused <span class="elsevierStyleSup">68</span>Ga-DOTA-TOC PET/CT this lesion was highly suspected for tumour residuum of the left humerus.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alexander Stephan Kroiss, Christian Uprimny, Barry Lynn Shulkin, Leonhard Gruber, Andreas Frech, Thomas Jazbec, Pierre Pascal Girod, Christoph Url, Claudius Thomé, Herbert Riechelmann, Georg Mathias Sprinzl, Gustav Fraedrich, Irene Johanna Virgolini" "autores" => array:13 [ 0 => array:2 [ "nombre" => "Alexander Stephan" "apellidos" => "Kroiss" ] 1 => array:2 [ "nombre" => "Christian" "apellidos" => "Uprimny" ] 2 => array:2 [ "nombre" => "Barry Lynn" "apellidos" => "Shulkin" ] 3 => array:2 [ "nombre" => "Leonhard" "apellidos" => "Gruber" ] 4 => array:2 [ "nombre" => "Andreas" "apellidos" => "Frech" ] 5 => array:2 [ "nombre" => "Thomas" "apellidos" => "Jazbec" ] 6 => array:2 [ "nombre" => "Pierre Pascal" "apellidos" => "Girod" ] 7 => array:2 [ "nombre" => "Christoph" "apellidos" => "Url" ] 8 => array:2 [ "nombre" => "Claudius" "apellidos" => "Thomé" ] 9 => array:2 [ "nombre" => "Herbert" "apellidos" => "Riechelmann" ] 10 => array:2 [ "nombre" => "Georg Mathias" "apellidos" => "Sprinzl" ] 11 => array:2 [ "nombre" => "Gustav" "apellidos" => "Fraedrich" ] 12 => array:2 [ "nombre" => "Irene Johanna" "apellidos" => "Virgolini" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X1830163X" "doi" => "10.1016/j.remn.2018.09.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X1830163X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300752?idApp=UINPBA00004N" "url" => "/22538089/0000003800000002/v1_201903020621/S2253808918300752/v1_201903020621/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S225380891830106X" "issn" => "22538089" "doi" => "10.1016/j.remnie.2018.10.014" "estado" => "S300" "fechaPublicacion" => "2019-03-01" "aid" => "1029" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Rev Esp Med Nucl Imagen Mol. 2019;38:80-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Tumor characteristics of lung cancer in predicting axillary lymph node metastases" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "80" "paginaFinal" => "86" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Características tumorales del cáncer de pulmón para predecir metástasis en los ganglios axilares" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 3537 "Ancho" => 2500 "Tamanyo" => 766846 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">67 years old male patient, histopathologic SCLC. PET/CT at diagnosis showing primary tumor (47<span class="elsevierStyleHsp" style=""></span>mm in diameter and SUVmax 13.7), right axillary lymph nodes (13<span class="elsevierStyleHsp" style=""></span>mm and SUVmax 5.1) and adrenal, liver, ipsilateral lung and bone metastases. Histopthologic lymph node metastases were confirmed. (a) MIP. (b) Coronal PET (white arrow ALM). (c) Coronal fusion. (d) Coronal CT (white arrow ALM). (e) Lymph node metastasis of SCLC (red arrow: necrosis, blue arrow: small cell carcinoma).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Funda Üstün, Burcu Tokuc, Ebru Tastekin, Gülay Durmuş Altun" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Funda" "apellidos" => "Üstün" ] 1 => array:2 [ "nombre" => "Burcu" "apellidos" => "Tokuc" ] 2 => array:2 [ "nombre" => "Ebru" "apellidos" => "Tastekin" ] 3 => array:2 [ "nombre" => "Gülay" "apellidos" => "Durmuş Altun" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X18300738" "doi" => "10.1016/j.remn.2018.09.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X18300738?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S225380891830106X?idApp=UINPBA00004N" "url" => "/22538089/0000003800000002/v1_201903020621/S225380891830106X/v1_201903020621/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Clinical and prognostic value of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in recurrent endometrial carcinoma" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "87" "paginaFinal" => "93" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Domenico Albano, Valentina Zizioli, Franco Odicino, Raffaele Giubbini, Francesco Bertagna" "autores" => array:5 [ 0 => array:4 [ "nombre" => "Domenico" "apellidos" => "Albano" "email" => array:1 [ 0 => "doalba87@libero.it" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Valentina" "apellidos" => "Zizioli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Franco" "apellidos" => "Odicino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Raffaele" "apellidos" => "Giubbini" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:3 [ "nombre" => "Francesco" "apellidos" => "Bertagna" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Obstetrics and Gynecology, Spedali Civili Brescia, Brescia, Italy" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Valor clínico y pronóstico de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG en el cáncer de endometrio recurrente" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 975 "Ancho" => 2178 "Tamanyo" => 123780 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Progression free survival (a) and overall survival (b) curves according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT results.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Endometrial carcinoma (EC) is a common gynecological cancer with an overall good prognosis, except in cases of advanced EC or with recurrence.<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">1,2</span></a> Common symptomatology usually leads to early diagnosis and favorable survival in most cases, but there is a subset of EC that presents poorer prognosis. The 5-year survival for early-stage disease is as high as 95% but it rapidly declines to 67% for stage III and 16% for stage IV disease.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">3</span></a> The treatment of EC usually involves surgery with or without adjuvant therapy (radiotherapy, chemotherapy or both); the post-treatment surveillance includes physical examination, conventional imaging (CI) studies, like ultrasound, computed tomography (CT) and/or magnetic resonance imaging (MRI), and post-treatment serum levels of Cancer Antigen (CA) 125. CA-125 has been shown to be a useful indicator of recurrence, but may have low specificity being able to be associated with both benign and malignant conditions<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">4</span></a>; moreover, this marker cannot show the anatomical localization of recurrent disease. Considering the poor prognosis of recurrent EC, it is crucial to define an effective diagnostic modality in the management of patients who are suspected to have recurrence. CI exams may not be very accurate in the detection of tumor recurrence<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">5</span></a>; in fact it is difficult for these imaging modalities to correctly differentiate between tumor recurrence and postsurgical or post-radiotherapy changes.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">5</span></a> The fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (<span class="elsevierStyleSup">18</span>F-FDG PET/CT), if performed after an adequate time interval following therapy, may be useful in this field.</p><p id="par0010" class="elsevierStylePara elsevierViewall">The definite role of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in evaluating EC is not completely established. Limited studies are available in the literature regarding the usefulness of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in recurrent EC<a class="elsevierStyleCrossRefs" href="#bib0190"><span class="elsevierStyleSup">6–15</span></a> and some of these studies present limitations like the use of <span class="elsevierStyleSup">18</span>F-FDG PET alone without CT,<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">7–10</span></a> the heterogeneous population included (cervical and endometrial cancers analyzed together)<a class="elsevierStyleCrossRefs" href="#bib0215"><span class="elsevierStyleSup">11,12</span></a> and the limited sample of patients included.<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">9,11,14–16</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">The aim of this retrospective study was to assess the diagnostic performance, the prognostic value and the impact on therapeutic management of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in a large sample of patients with suspected recurrent endometrial carcinoma.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Patients</span><p id="par0020" class="elsevierStylePara elsevierViewall">We retrospectively evaluated 157 women (average age 61.8, range 31–84) with an histological diagnosis of endometrial carcinoma who underwent <span class="elsevierStyleSup">18</span>F-FDG PET/CT for restaging purpose and suspected recurrence.</p><p id="par0025" class="elsevierStylePara elsevierViewall">The clinical features of patients are summarized in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. All patients underwent abdominal hysterectomy plus bilateral salpingo-oophorectomy and in 56 cases bilateral pelvic lymphadenectomy was also performed. Forty patients (25%) did not receive postsurgical adjuvant therapy; adjuvant external pelvic radiotherapy was administered in 60 cases (39%), chemotherapy in 32 (20%) cases and a combination of chemotherapy and radiotherapy in 25 (16%). At the time of diagnosis, 58 patients were in stage I according to The International Federation of Gynecology and Obstetrics (FIGO) classification,<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">17</span></a> 29 in stage II, 62 in stage III and 8 in stage IV. The most common EC histotype was endometrioid adenocarcinoma in 125 patients, followed by serous carcinoma and clear cell carcinoma in 16 cases respectively. Recurrence was suspected on the basis of elevated tumor marker levels (considering CA 125 higher than 35<span class="elsevierStyleHsp" style=""></span>U/mL) in 18 women, because of imaging findings on CI exams in 80 women, due to clinical suspicion in symptomatic patients and higher CA125 level in 28 cases, and because of both elevated CA 125 level and findings on CI in the remaining 31 patients. Follow-up information was used to assess the disease status in order to evaluate the progression free survival (PFS), the overall survival (OS) and the impact of PET/CT on the therapeutic approach (change in therapy or “wait and watch” approach).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080"><span class="elsevierStyleSup">18</span>F-FDG PET/CT imaging and interpretation</span><p id="par0030" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">18</span>F-FDG PET/CT scans were performed in accordance with a standard whole-body oncological protocol following the guidelines of the European Association of Nuclear Medicine (EANM).<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">18</span></a><span class="elsevierStyleSup">18</span>F-FDG PET/CT was performed after at least 6<span class="elsevierStyleHsp" style=""></span>h fasting and with glucose level lower than 130<span class="elsevierStyleHsp" style=""></span>mg/dl. An activity of 3.5–4.5<span class="elsevierStyleHsp" style=""></span>MBq/kg of <span class="elsevierStyleSup">18</span>F-FDG was administered intravenously and images were acquired 60<span class="elsevierStyleHsp" style=""></span>min after injection from the skull base to the mid-thigh on a Discovery ST PET/CT tomograph or a Discovery 690 (General Electric Company—GE<span class="elsevierStyleSup">®</span>—Milwaukee, WI, USA) with standard parameters (CT: 80<span class="elsevierStyleHsp" style=""></span>mA, 120<span class="elsevierStyleHsp" style=""></span>kV; 2.5-4<span class="elsevierStyleHsp" style=""></span>min per bed-PET-step of 15<span class="elsevierStyleHsp" style=""></span>cm); reconstruction was performed with a 128<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>128 matrix and 60<span class="elsevierStyleHsp" style=""></span>cm field of view. Patients were instructed to void before imaging acquisition, no oral or intravenous contrast agents were administrated or bowel preparation used for any patient; written consent was obtained before studies.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value body weight (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG). Readers had knowledge of clinical history, and every focal tracer uptake deviating from physiological distribution and background was regarded as suggestive of disease; it was defined as <span class="elsevierStyleSup">18</span>F-FDG activity higher than the surrounding tissue and blood-pool activity on visual analysis. We measured the SUV of detectable lesions by drawing a region of interest (ROI) over the area of maximum activity and the SUVmax was calculated as the highest SUV of the pixels within the ROI. The lesion with the highest <span class="elsevierStyleSup">18</span>F-FDG uptake in each patient was taken as the reference lesion and the SUVmax, was calculated for analysis. MTV was measured from attenuation-corrected <span class="elsevierStyleSup">18</span>F-FDG-PET images using a SUV-based automated contouring program (Advantage Workstation 4.6, GE HealthCare) with an isocounter threshold method based on 41% of the SUVmax, as previously recommended by European Association of Nuclear Medicine because of its high inter-observer reproducibility.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">18</span></a> Total MTV (tMTV) was obtained by the sum of all lesions, local and non local. TLG was calculated as the sum of the product of MTV of each lesion and its SUVmean.</p><p id="par0040" class="elsevierStylePara elsevierViewall">Conventional imaging (CI), including contrast-enhanced CT if no contraindications and MRI, were used for comparison with <span class="elsevierStyleSup">18</span>F-FDG PET/CT scan when available and within an interval of maximum 30 days.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Reference standard</span><p id="par0045" class="elsevierStylePara elsevierViewall">A combination of clinical/imaging follow-up (CT, MRI, ultrasonography and/or PET/CT) for at least 12 months after restaging <span class="elsevierStyleSup">18</span>F-FDG PET/CT and/or histopathology (when available) was taken as the reference standard. Because histopathological confirmation of all lesions was not ethically and clinically feasible, histopathology was available only for 50 studies. Lesions demonstrating increase in size on radiologic follow-up examinations and/or increase in <span class="elsevierStyleSup">18</span>F-FDG uptake on subsequent PET/CT were considered as true positive; also lesions showing response to therapy were taken as true positive. Instead, lesions not showing any change or decrease in size and/or <span class="elsevierStyleSup">18</span>F-FDG uptake without any treatment were considered as false positive.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Statistical analysis</span><p id="par0050" class="elsevierStylePara elsevierViewall">All statistical analysis was carried out using Statistical Package for Social Science (SPSS) version 23.0 for Windows (IBM, Chicago, Illinois, USA) and MedCalc Software version 17.1 for Windows (Ostend, Belgium). A <span class="elsevierStyleItalic">p-</span>value<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05 was considered statistically significant. The descriptive analysis of categorical variables comprised the calculation of simple and relative frequencies. The numeric variables were described as mean, minimum and maximum.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Univariate logistic regression analysis was performed to assess the relationship between qualitative <span class="elsevierStyleSup">18</span>F-FDG PET/CT (<span class="elsevierStyleSup">18</span>F-FDG avidity) and the other parameters. Variables with <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05 in the univariate analysis were further analyzed using multivariate logistic regression analysis to determinate which variables were independently associated.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Using final diagnosis as a reference, sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were calculated based on Bayes's law, with 95% confidence intervals (CIs). PFS was determined considering the time interval between restaging PET/CT and the appearance of clinical and/or radiological progression. OS was defined as the time interval between restaging PET/CT and death. PFS and OS were computed using Kaplan–Meier curves. Univariate and multivariate Cox proportional hazards models were fitted in the whole sample. The relationship between outcome and the variables included was summarized by hazard ratios (HR) with 95% confidence intervals (95% CI).</p><p id="par0065" class="elsevierStylePara elsevierViewall">For the entire population, receiver operating characteristic (ROC) curve analysis was used to identify the optimal cutoff point of semiquantitative parameters in the light of which interpret the results of progression free survival (PFS) and overall survival (OS) (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100"><span class="elsevierStyleSup">18</span>F-FDG PET/CT performance in detecting recurrence</span><p id="par0070" class="elsevierStylePara elsevierViewall">Based on the reference standard mentioned in the Methods section, a definitive diagnosis of recurrent disease at the time of restaging PET/CT was present in 81 patients, whereas there was no recurrent disease in 76 patients. <span class="elsevierStyleSup">18</span>F-FDG PET/CT was positive in 79 scans (50.3%) showing the presence of at least one hypermetabolic lesion consistent with EC local recurrence or metastatic lesion, while in the remaining 78 studies (49.7%) no areas of increased <span class="elsevierStyleSup">18</span>F-FDG uptake were discovered.</p><p id="par0075" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">18</span>F-FDG PET/CT sites of recurrence included local pelvic relapse in 9 cases, locoregional lymph nodes in 30 patients, both local recurrence and regional lymph nodes in 9 patients; distant metastatic disease was observed in 18 studies, 8 studies showed both locoregional nodes and metastatic disease and 5 local pelvic relapse and distant metastases together. Lung was the most common site of distant metastasis (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>15), followed by peritoneum (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>6), liver and bone (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>3 each). Other rarer sites of metastatic involvement were intestine, brain, or disseminate disease involving different organs (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">Suspected recurrence of EC was confirmed in 78/79 patients with a positive <span class="elsevierStyleSup">18</span>F-FDG-PET scan (as reference, other imaging and/or follow-up clinical data were used in 30 patients and histopathology in 49). In one patient, <span class="elsevierStyleSup">18</span>F-FDG PET/CT showed a false positive finding with an increased <span class="elsevierStyleSup">18</span>F-FDG uptake in several iliac nodes, later diagnosed as lymph nodal chronic inflammatory disease. Instead, in 75/78 patients with a negative <span class="elsevierStyleSup">18</span>F-FDG-PET, other imaging and/or follow-up clinical data confirmed the absence of recurrent disease. In three cases PET/CT failed to detect recurrences; in two patients due to the presence of small lung nodular lesions under the spatial resolution of the PET/CT scanner (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>) and in one patient with peritoneal disease PET/CT showed no significant increased <span class="elsevierStyleSup">18</span>F-FDG uptake.</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0085" class="elsevierStylePara elsevierViewall">Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of <span class="elsevierStyleSup">18</span>F-FDG-PET/CT were 96%, 99%, 99%, 96% and 97%, respectively. Positive and negative likelihood ratios were 73.19 and 0.04, respectively</p><p id="par0090" class="elsevierStylePara elsevierViewall">Comparing the two groups (patients with positive and negative PET/CT) in terms of age, histotype and primary treatment there were no significant differences (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). Patients with hypermetabolic lesions presented more frequently a high stage according to FIGO classification compared to patients with negative PET/CT scans. This evidence was confirmed both in univariate and multivariate analysis.</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">In patients with a positive <span class="elsevierStyleSup">18</span>F-FDG PET/CT, average SUVmax of the lesion with higher, FDG uptake was 13.1<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>4.7 (range 2.7-33), MTV 28.35<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>41.6<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleSup">3</span> (1-250) and TLG 230<span class="elsevierStyleHsp" style=""></span>±381 (1.5-2310).</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Comparison with CI</span><p id="par0100" class="elsevierStylePara elsevierViewall">Comparative CI (contrast enhanced CT, MRI) was available for 150 PET-CT studies: abdominal MRI in 8 cases and CT in 142 cases. CT was done as segmental examination of chest, abdomen and pelvis. Of these 150 CI examinations, 102 were positive for recurrence and among them, 74 were true positive, whereas 28 were false-positive; the remaining 48 CI studies were negative with 46 true negative scans and 2 false negative. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of CI were 97%, 62%, 72%, 96%, 80%, respectively. Positive and negative likelihood ratios were 2.57 and 0.04, respectively (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). CI and PET/CT were concordant in 120 patients and discordant in 30 patients.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110"><span class="elsevierStyleSup">18</span>F-FDG PET/CT prognostic role</span><p id="par0105" class="elsevierStylePara elsevierViewall">After a mean follow-up period of 39 months (range 2–120), relapse or progression of disease occurred in 58 (37%) patients with an average time of 22.1 months (range: 2-96 months) from the restaging PET/CT and death occurred in 37 (23%) patients with an average time of 27.6 months (range 2-117). Among the 99 patients without disease progression, 81 were disease-free and 18 had stable disease at the last follow-up control. The estimated 3-year PFS and OS rates were 86% and 71% respectively, while 5-year PFS and OS rates were 67% and 56%, respectively. A positive <span class="elsevierStyleSup">18</span>F-FDG PET/CT was significantly associated with shorter PFS and OS compared to unremarkable PET/CT scan, both at 3-years (PFS 37% vs 91% <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OS 54% vs 98% <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) and at 5-years (PFS 27% vs 77% <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001; OS 40% vs 92% <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>). In the univariate Cox regression analysis, an unremarkable <span class="elsevierStyleSup">18</span>F-FDG PET/CT scan was associated with a significantly longer survival rate (PFS and OS) compared to a positive scan (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). Similarly, advanced stage disease (III and IV acc. to FIGO), other than endometriod carcinoma histotype (serous or clear cell carcinoma), nodal disease and distant metastatic disease correlated with a shorter PFS and OS compared to early stage (I, II), endometriod carcinoma histotype, the absence of nodal disease and the absence of metastatic disease. However, at multivariate analysis, PET/CT positivity and advanced FIGO stage disease were confirmed as the only variables with independent prognostic value. Instead by evaluating semiquantitative PET/CT parameters in those patients with positive findings (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>79), SUVmax, MTV and TLG failed to show a significant predictive value both for PFS and OS (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Impact of <span class="elsevierStyleSup">18</span>F-FDG PET/CT on therapeutic approach</span><p id="par0110" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleSup">18</span>F-FDG PET/CT results had a significant impact on the therapeutic approach in 33 patients (21%). In 28 cases of negative PET/CT and suspected disease at conventional imaging techniques, PET/CT results demonstrated to be true negative and patients remained in “watch and wait” approach avoiding unnecessary invasive therapies. On the contrary, in 5 patients with a positive PET/CT scan, the therapeutic regimen was modified switching from local therapy to chemotherapy due to the detection of disseminate disease in comparison with local disease detected at CT.</p></span></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Discussion</span><p id="par0115" class="elsevierStylePara elsevierViewall">EC is a very common gynecological malignancy that generally presents good prognosis but in patients who develop recurrence outcome is unfavorable. Usually recurrence happens within 2 years of initial treatment.<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">2</span></a> Surely, an early and accurate detection of recurrence in patients with EC is expected to have a significant impact on management and survival outcomes. Conventional imaging examinations, like CT and MRI, and biochemical analysis (CA125) have been shown to be useful in demonstrating recurrence, but may have low specificity and may not localize the site of recurrent disease.<a class="elsevierStyleCrossRefs" href="#bib0180"><span class="elsevierStyleSup">4–6</span></a> Considering the poor prognosis of recurrent EC, the identification of a helpful modality to detect recurrence is mandatory. To overcome the limitations of imaging modalities based on morphology, <span class="elsevierStyleSup">18</span>F-FDG PET/CT is a molecular imaging technique that can assess the metabolic activity of the tumor. Some studies demonstrated a better diagnostic accuracy of <span class="elsevierStyleSup">18</span>F-FDG PET/CT compared to other conventional imaging modalities in restaging EC.<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">9,19</span></a> The clinical role of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in the management of post-treatment EC patients is relatively less described. Several authors<a class="elsevierStyleCrossRefs" href="#bib0195"><span class="elsevierStyleSup">7–16,19–21</span></a> have reported high clinical diagnostic accuracy of integrated PET/CT for post-therapy surveillance of patients with EC and suspicious of recurrence. According to literature data, the patient-based pooled sensitivity and specificity of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in post-therapy surveillance of EC were 96% (range 87%–100%) and 93% (range 79%–100%), respectively (<a class="elsevierStyleCrossRef" href="#tbl0025">Table 5</a>). In our study, the results were comparable to the literature; we demonstrated that <span class="elsevierStyleSup">18</span>F-FDG PET/CT performed in the restaging process has optimal diagnostic performances and is higher than conventional imaging. In fact, the sensitivity and specificity in our study were 96% and 99% respectively, while diagnostic accuracy was 97%. Ryu et al.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">7</span></a> evaluated the role of PET alone in 127 asymptomatic post therapy patients showing a sensitivity of 100% and a specificity of 88%. Also Saga et al.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">9</span></a> in their study found PET to be highly sensitive (100%) and specific (88.2%) for detecting recurrence. Kitajima et al.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">13</span></a> found PET alone to be inferior to PET/CT, with lower sensitivity (80% vs. 93%), specificity (80% vs. 93%), and diagnostic accuracy (80% vs. 93%) in detecting recurrence. Recently Sharma et al.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">19</span></a> demonstrated good sensitivity and specificity but lower compared to our results. Moreover, they compared PET/CT and CI diagnostic accuracy in restaging patients with suspicion of recurrence and they discovered higher specificity and accuracy but comparable sensitivity. Also in our work, we demonstrated a superior detection rate of PET/CT compared to CI in specificity and accuracy (99% vs 62%, 97% vs 80%) and similar sensitivity (96% vs 97%). Verification by surgical exploration or imaging-guided biopsy of superficial lymph nodes, liver, lung or other distant metastases was performed if available. Otherwise, the results of PET/CT were confirmed by clinical or radiologic outcomes, particularly in patients with disseminated disease.</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">In this study, we demonstrated that positive <span class="elsevierStyleSup">18</span>F-FDG PET/CT and advanced stage disease were the only independent prognostic factors of outcome, both for PFS and OS. There is a strong relation between advanced stage and the probability of a positive restaging PET/CT: patients with FIGO stage III or IV had more frequently PET/CT positive for recurrence. Other studied demonstrated significant prognostic value of PET/CT in EC in the staging process, before any treatment,<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">22–32</span></a> showing a significant role of PET/CT features, especially SUVmax and MTV value, in the prediction of outcome survival. In this regard, to the best of our knowledge, this is the first paper investigating the prognostic role of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in restaging patients affected by EC. Instead, SUVmax did not correlated with PFS and OS using a cutoff of 3.8 (derived by ROC curve analysis). This evidence was in opposition to several articles that demonstrated the positive role of SUVmax at staging in predicting prognosis.<a class="elsevierStyleCrossRefs" href="#bib0275"><span class="elsevierStyleSup">23–26</span></a> Only Chung et al.,<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">14</span></a> in a small sample of EC patients, showed that the 2-year PFS rate of patients with a negative PET/CT scan for recurrence was significantly better than for patients with a positive PET/CT (100% vs 33.7%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.015). In their study, all patients with negative PET/CT scans were still alive without evidence of disease at the last follow-up control; however, among patients with positive PET/CT scans 10/13 had progression of disease or relapse.</p><p id="par0125" class="elsevierStylePara elsevierViewall">In our work, the mean SUVmax of the recurrent lesions was 13.1 (range 2.7–33), similar to that documented by Chao et al.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">19</span></a> and higher than other studies,<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">8</span></a> possibly due to the higher number of patients and scans evaluated and the homogenous distribution of their clinico-pathological features.</p><p id="par0130" class="elsevierStylePara elsevierViewall">In our study MTV and TLG did not demonstrate prognostic features in recurrent EC. These parameters include both morphological and metabolic features and may be considered an expression of tumor aggressiveness together with tumor size characteristic, but their role is not completely understood and many open questions stay. Different methods are available and a wide range of threshold levels have been proposed to calculate the volume-based PET/CT parameters without univocal consensus. Moreover, there are no published technical references about the methodology for the calculation of the volume based PET parameters and definition of specific cutoff values in endometrial cancer. Several studies<a class="elsevierStyleCrossRefs" href="#bib0305"><span class="elsevierStyleSup">29–32</span></a> demonstrated the prognostic role of MTV and TLG in survival outcome of EC but these parameters were calculated at pretreatment PET/CT; no previous papers about possible prognostic role of MTV and TLG at restaging were done.</p><p id="par0135" class="elsevierStylePara elsevierViewall">Moreover, our results confirm the possible role of PET/CT to change patient's management and therapeutic approach in a significant rate of patient (about 20%); in fact in 33 patients, <span class="elsevierStyleSup">18</span>F-FDG PET/CT had a positive impact avoiding unnecessary therapies in 28 cases and changing the therapeutic approach in 5 patients. Other authors<a class="elsevierStyleCrossRefs" href="#bib0205"><span class="elsevierStyleSup">9,10,15,16</span></a> confirmed this result underlying the potential usefulness of PET/CT in the management of EC.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Based on the findings of this paper, <span class="elsevierStyleSup">18</span>F-FDG PET/CT seems to be an accurate method for detection and localization of local and distant recurrences in patients with EC showing good sensitivity and specificity and a significant impact on the clinical decision-making.</p><p id="par0145" class="elsevierStylePara elsevierViewall">The limitations of our study are the retrospective nature of the study design, the use of two different PET/CT devices and the absence of histological confirmation of all findings (the most reliable method but not ethically or clinically feasible).</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Conclusions</span><p id="par0150" class="elsevierStylePara elsevierViewall">In conclusion, in our study we demonstrated that <span class="elsevierStyleSup">18</span>FDG PET/CT was a highly sensitive and specific modality for detecting recurrence in post-therapy patients of endometrial carcinoma with suspected recurrence and had a significant clinical impact changing the therapeutic approach. PET/CT diagnostic accuracy seemed to be better than CI. Furthermore, PET/CT results and FIGO stage were significantly correlated with outcome survival, both for PFS and OS, while SUVmax, MTV and TLG were not related to outcome survival.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conflict of interest</span><p id="par0155" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1157603" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Purpose" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Materials and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1084758" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1157604" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1084757" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Materials and methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Patients" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "F-FDG PET/CT imaging and interpretation" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Reference standard" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "F-FDG PET/CT performance in detecting recurrence" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Comparison with CI" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "F-FDG PET/CT prognostic role" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "Impact of F-FDG PET/CT on therapeutic approach" ] ] ] 7 => array:2 [ "identificador" => "sec0060" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0065" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2018-08-07" "fechaAceptado" => "2018-09-19" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1084758" "palabras" => array:5 [ 0 => "Endometrial carcinoma" 1 => "PET/CT" 2 => "Endometrium" 3 => "<span class="elsevierStyleSup">18</span>F-FDG PET/CT" 4 => "Recurrence" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1084757" "palabras" => array:5 [ 0 => "Carcinoma de endometrio" 1 => "PET/TC" 2 => "Endometrio" 3 => "<span class="elsevierStyleSup">18</span>F-FDG PET/TC" 4 => "Recurrencia" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Purpose</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Endometrial carcinoma (EC) is a cancer with a good overall prognosis, except in cases of recurrent or advanced EC. The aim of this study was to assess the diagnostic performance, the prognostic value and the impact on therapeutic management of <span class="elsevierStyleSup">18</span>F-FDG-PET/CT in suspected recurrent EC.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Materials and methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">We retrospectively evaluated 157 patients with histologically proven EC and restaging <span class="elsevierStyleSup">18</span>F-FDG-PET/CT for suspected recurrence. The PET images were analyzed visually and semi-quantitatively by measuring SUVmax, MTV and TLG. A combination of clinical/imaging follow-up and/or histopathology was taken as reference standard. PFS and OS were computed using Kaplan–Meier curves.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Seventy-nine patients had positive <span class="elsevierStyleSup">18</span>F-FDG-PET/CT showing the presence of at least one hypermetabolic lesion consistent with recurrence, while the remaining 78 were negative. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of <span class="elsevierStyleSup">18</span>F-FDG-PET/CT were 96%, 99%, 99%, 96%, 97% respectively and were higher compared to conventional imaging: 97%, 62%, 72%, 96%, 80%. After a mean follow-up of 39 months, relapse/progression occurred in 58 patients and death in 37 with an average time of 22.1 and 27.6 months respectively. A positive <span class="elsevierStyleSup">18</span>F-FDG-PET/CT and advanced FIGO stage were significantly associated with shorter PFS and OS. PET/CT results had a significant impact on therapeutic approach in 33 patients: avoiding unnecessary therapies in 28 and modifying therapy in 5.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleSup">18</span>F-FDG-PET/CT has a very good diagnostic performance in patients with suspected recurrent EC and has an important prognostic value in assessing PFS and OS. Moreover, PET/CT allowed for a change in treatment decision in about 20% of cases.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Purpose" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Materials and methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">El carcinoma endometrial (CE) es un cáncer con un buen pronóstico general, excepto en los casos de CE recurrente o avanzado. El objetivo de este estudio fue evaluar el rendimiento diagnóstico, y pronóstico y el impacto en el manejo terapéutico de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG en la sospecha de CE recurrente.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Se evaluaron retrospectivamente 157 pacientes con CE histológicamente probado y reestadificación de PET/TC con <span class="elsevierStyleSup">18</span>F-FDG por sospecha de recurrencia. Las imágenes PET se analizaron visualmente y semicuantitativamente midiendo SUVmax, MTV y TLG. Se tomó como referencia una combinación de seguimiento clínico/radiológico/histopatológico. PFS y OS se calcularon usando las curvas de Kaplan-Meier.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Setenta y nueve pacientes tuvieron una PET/TC con <span class="elsevierStyleSup">18</span>F-FDG positiva que mostró la presencia de al menos una lesión hipermetabólica compatible con recurrencia, mientras que los 78 restantes fueron negativos. La sensibilidad, especificidad, valor predictivo positivo, valor predictivo negativo y precisión de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG fueron 96%, 99%, 99%, 96%, 97% respectivamente y fueron más altos en comparación con las imágenes convencionales: 97%, 62%, 72%, 96%, 80%. Después de un seguimiento medio de 39 meses, la recaída/progresión ocurrió en 58 pacientes y la muerte en 37 con un tiempo promedio de 22,1 y 27,6 meses respectivamente. Una PET/TC con <span class="elsevierStyleSup">18</span>F-FDG positiva y un estadio FIGO avanzado se asociaron significativamente con un PFS y OS más cortos. Los resultados de PET/TC tuvieron un impacto significativo en el abordaje terapéutico en 33 pacientes: evitando terapias innecesarias en 28 y modificando la terapia en 5.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">La <span class="elsevierStyleSup">18</span>F-FDG-PET/TC tiene un muy buen rendimiento diagnóstico en pacientes con sospecha de recurrente CE, y tiene un importante valor pronóstico en la evaluación de SLP y SG. Además, la PET/TC permitió un cambio en la decisión de tratamiento en aproximadamente el 20% de los casos.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Please cite this article as: Albano D, Zizioli V, Odicino F, Giubbini R, Bertagna F. Valor clínico y pronóstico de la PET/TC con <span class="elsevierStyleSup">18</span>F-FDG en el cáncer de endometrio recurrente. Rev Esp Med Nucl Imagen Mol. 2019;38:87–93.</p>" ] ] "multimedia" => array:8 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 638 "Ancho" => 1740 "Tamanyo" => 100760 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">A representative case of a positive <span class="elsevierStyleSup">18</span>F-FDG PET/CT in a 64-year old woman with increased CA-125 marker and endometroid carcinoma previously treated with surgery plus RTT. Maximum intensity projection (MIP, a) showing the presence of multiple FDG uptake foci. Axial PET and PET/CT images demonstrating hypermetabolic lesions in the liver (b, c), in the bone corresponding to sternum and vertebra (d, e) and in the left lung (f, g).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1764 "Ancho" => 1740 "Tamanyo" => 132600 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">A representative case of a false negative <span class="elsevierStyleSup">18</span>F-FDG PET/CT in a 59-year old patient with endometroid carcinoma who underwent restaging <span class="elsevierStyleSup">18</span>F-FDG PET/CT for suspected relapse. MIP (a) detecting no increased FDG uptake. Axial PET (b, d) and PET/CT fused (c, e) images showing the presence of pulmonary nodules with no significant FDG increased uptake.</p>" ] ] 2 => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 975 "Ancho" => 2178 "Tamanyo" => 123780 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Progression free survival (a) and overall survival (b) curves according to <span class="elsevierStyleSup">18</span>F-FDG PET/CT results.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Frequency \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">% \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Age average (range)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61.8 (31–84) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Primary FIGO stage</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">37 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">18 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">62 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Histotype</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Endometrioid adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">125 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">80 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Serous carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Clear cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">10 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">Treatment</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">40 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">25 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">20 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>radiotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>radiotherapy<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>chemotherapy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">25 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleSup"><span class="elsevierStyleItalic">18</span></span><span class="elsevierStyleItalic">F-FDG PET/CT result</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">50.3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">78 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">49.7 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1976541.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of 157 patients.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">AUC:</span> area under curve; <span class="elsevierStyleItalic">CI</span>: confidence interval; <span class="elsevierStyleItalic">sens:</span> sensibility; <span class="elsevierStyleItalic">spec:</span> specificity; <span class="elsevierStyleItalic">SUV:</span> standardized uptake value; <span class="elsevierStyleItalic">tMTV:</span> total metabolic tumor volume; <span class="elsevierStyleItalic">TLG:</span> total lesion glycolysis.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Parameter \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Cutoff \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">AUC (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sens (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Spec (95% CI) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SUVmax \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.570 (0.453-0.682) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.328 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">100% (92.2-100) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">25% (11.5-43.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">tMTV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">6.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.524 (0.408-0.637) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.721 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">76.6% (62-87.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">40.6% (23.7-59.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TLG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">139 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.498 (0.384-0.613) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.980 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">66% (50.7-79.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">47 (29.1-65.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1976540.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Metabolic PET/CT parameters cutoff calculated using receiver operating characteristic (ROC) curve analysis considering the entire population.</p>" ] ] 5 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">PET/CT detection rate</th><th class="td" title="table-head " align="left" valign="top" scope="col"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Positive (%), <span class="elsevierStyleItalic">n</span> 79 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Negative (%), <span class="elsevierStyleItalic">n</span> 78 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Age average</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">63.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">60.1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.090 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Stage FIGO</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.030<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> (0.018) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>I \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (29%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">35 (46%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>II \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (22%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 (15%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>III \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32 (40%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">30 (38%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IV \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7 (9%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1 (1%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Histotype</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.052 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Endometrioid adenocarcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">58 (73%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">67 (86%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Serous carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (13%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 (8%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Clear cell carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (14%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 (6%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="4" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Primary treatment</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.208 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">23 (29%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (22%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>CMT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 (20%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">16 (20%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>RTT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">32 (41%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">28 (36%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Surgery<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>CMT<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>RTT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (10%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 (22%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1976537.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Between parenthesis is present the <span class="elsevierStyleItalic">p</span> value of multivariate analysis.</p> <p class="elsevierStyleNotepara" id="npar0010"><span class="elsevierStyleItalic">CMT</span>: chemotherapy; <span class="elsevierStyleItalic">RTT</span>: radiotherapy.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Comparison between patients with positive and negative <span class="elsevierStyleSup">18</span>F-FDG PET/CT scans.</p>" ] ] 6 => array:8 [ "identificador" => "tbl0020" "etiqueta" => "Table 4" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at4" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="table-head ; entry_with_role_rowhead " align="left" valign="top" scope="col">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Univariate PFS</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Multivariate PFS</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Univariate OS</th><th class="td" title="table-head " colspan="2" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Multivariate OS</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR (95% IC) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR (95% IC) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR (95% IC) \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">HR (95% IC) \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Stage III–IV (FIGO) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.012 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.527 (0.30–0.86) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.020 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.949 (1.11–3.42) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.333 (0.16–0.62) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3.632 (1.67–7.89) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Not endometrioid carcinoma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.026 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.022 (0.21–0.90) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.465 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.263 (0.67–2.36) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.021 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.450 (0.14–0.85) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.633 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.201 (0.56–2.54) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Lymph-nodal disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.320 (0.12–0.42) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.309 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.439 (0.71–2.89) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.273 (0.08–0.39) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.071 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.242 (0.93–5.37) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Distant metastases \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.350 (0.12–0.48) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.269 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.450 (0.75–2.79) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.314 (0.08–0.46) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.070 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2.164 (0.94–4.97) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">PET/CT pos \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.159 (0.10–0.30) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4.414 (1.82–10.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top"><0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.080 (0.08–0.30) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">5.847 (1.40–24.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">SUVmax<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>3.8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.073 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 (0.09–1.12) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.172 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.000 (0.07–1.59) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">MTV<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>6.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.217 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.660 (0.36–1.26) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.370 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.702 (0.33–1.49) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TLG<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>139 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.706 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1.12 (0.61–2.05) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.247 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.674 (0.31–1.34) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1976539.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Cox regression analysis for the prediction of PFS and OS.</p>" ] ] 7 => array:8 [ "identificador" => "tbl0025" "etiqueta" => "Table 5" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at5" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Author \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Year \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">No. pts \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Device \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mean age \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sensibility \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Specificity \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Belhocine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2002 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">96% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">78% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Saga \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2003 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">62 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100%<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">88%<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chao \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2006 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">55 (median) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">87% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">97% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sironi \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2007 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">13 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Kitajima \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2008 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">59 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">93% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">93% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Park \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2008 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">88 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">83% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Chung \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2008 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Kitajima \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2010 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50 (median) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">92% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">97% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ryu \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2010 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">127 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">52 (median) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">88% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ozcan kara \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2011 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">31 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">100% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">96% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sharma \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2012 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">101 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">56.9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">89% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">94% \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Our study \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2018 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">157 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">PET/CT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">61 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">96% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">99% \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1976538.png" ] ] ] "notaPie" => array:1 [ 0 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">PET was evaluated with the help of CT/MRI for anatomic information.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Summary of studies in literature including at least 10 patients with endometrial cancer and restaging PET/CT.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:32 [ 0 => array:3 [ "identificador" => "bib0165" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis treatment and follow-up" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group" "etal" => true "autores" => array:6 [ 0 => "N. Colombo" 1 => "C. Creutzberg" 2 => "F. Amant" 3 => "T. Bosse" 4 => "A. González-Martín" 5 => "J. Ledermann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/IGC.0000000000000609" "Revista" => array:7 [ "tituloSerie" => "Int J Gynecol Cancer" "fecha" => "2016" "volumen" => "26" "paginaInicial" => "2" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26645990" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0213911112000581" "estado" => "S300" "issn" => "02139111" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0170" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Advances in the management of endometrial adenocarcinoma. A review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "W.P. Irvin" 1 => "L.W. Rice" 2 => "R.S. Berkowitz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "J Reprod Med" "fecha" => "2002" "volumen" => "47" "paginaInicial" => "173" "paginaFinal" => "189" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11933681" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0175" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cancer statistics, 2013" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R. Siegel" 1 => "D. Naishadham" 2 => "A. Jemal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3322/caac.21166" "Revista" => array:6 [ "tituloSerie" => "CA Cancer J Clin" "fecha" => "2013" "volumen" => "63" "paginaInicial" => "11" "paginaFinal" => "30" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23335087" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0180" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.L. Cherchi" 1 => "S. Dessole" 2 => "G.A. Ruiu" 3 => "G. Ambrosini" 4 => "M. Farina" 5 => "G. Capobianco" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur J Gynaecol Oncol" "fecha" => "1999" "volumen" => "20" "paginaInicial" => "315" "paginaFinal" => "317" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10475131" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0185" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Imaging in endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E. Epstein" 1 => "L. Blomqvist" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bpobgyn.2014.04.007" "Revista" => array:6 [ "tituloSerie" => "Best Pract Res Clin Obstet Gynaecol" "fecha" => "2014" "volumen" => "28" "paginaInicial" => "721" "paginaFinal" => "739" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24852891" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0190" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection of recurrence by <span class="elsevierStyleSup">18</span>F-FDG PET in patients with endometrial cancer showing no evidence of disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.-Y. Ryu" 1 => "K. Kim" 2 => "Y. Kim" 3 => "S.I. Park" 4 => "B.J. Kim" 5 => "M.H. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3346/jkms.2010.25.7.1029" "Revista" => array:6 [ "tituloSerie" => "J Korean Med Sci" "fecha" => "2010" "volumen" => "25" "paginaInicial" => "1029" "paginaFinal" => "1033" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20592894" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0195" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Positron emission tomography with fluorodesoxyglucose-F<span class="elsevierStyleSup">18</span> in follow-up of endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.C. Rebollo-Aguirre" 1 => "C. Ramos-Font" 2 => "M. Gallego Peinado" 3 => "M.E. Bellón-Guardia" 4 => "D. Cabello García" 5 => "A. Rodríguez-Fernández" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl" "fecha" => "2006" "volumen" => "25" "paginaInicial" => "359" "paginaFinal" => "366" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17173784" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0200" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Saga" 1 => "T. Higashi" 2 => "T. Ishimori" 3 => "M. Mamede" 4 => "Y. Nakamoto" 5 => "T. Mukai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Ann Nucl Med" "fecha" => "2003" "volumen" => "17" "paginaInicial" => "197" "paginaFinal" => "203" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12846541" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0205" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Usefulness of <span class="elsevierStyleSup">18</span>F-FDG PET in the post-therapy surveillance of endometrial carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "T. Belhocine" 1 => "C. De Barsy" 2 => "R. Hustinx" 3 => "J. Willems-Foidart" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-002-0878-2" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2002" "volumen" => "29" "paginaInicial" => "1132" "paginaFinal" => "1139" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12192557" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0210" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Sironi" 1 => "M. Picchio" 2 => "C. Landoni" 3 => "S. Galimberti" 4 => "M. Signorelli" 5 => "V. Bettinardi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-006-0251-y" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2007" "volumen" => "34" "paginaInicial" => "472" "paginaFinal" => "479" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17106701" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0215" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kitajima" 1 => "K. Suzuki" 2 => "Y. Nakamoto" 3 => "Y. Ohishi" 4 => "S. Sakamoto" 5 => "M. Senda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-010-1440-2" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2010" "volumen" => "37" "paginaInicial" => "1490" "paginaFinal" => "1498" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20386901" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0220" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Kitajima" 1 => "K. Murakami" 2 => "E. Yamasaki" 3 => "S. Hagiwara" 4 => "I. Fukasawa" 5 => "N. Inaba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12149-007-0087-y" "Revista" => array:6 [ "tituloSerie" => "Ann Nucl Med" "fecha" => "2008" "volumen" => "22" "paginaInicial" => "103" "paginaFinal" => "109" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18311534" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0225" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: a comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "P. Ozcan Kara" 1 => "T. Kara" 2 => "B. Kaya" 3 => "G. Kara Gedik" 4 => "O. Sari" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2011.06.001" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl Imagen Mol" "fecha" => "2012" "volumen" => "31" "paginaInicial" => "257" "paginaFinal" => "260" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23067527" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0230" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The clinical impact of [18F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.H. Chung" 1 => "W.J. Kang" 2 => "J.W. Kim" 3 => "N.H. Park" 4 => "Y.S. Song" 5 => "J.K. Chung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-007-0687-8" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2008" "volumen" => "35" "paginaInicial" => "1081" "paginaFinal" => "1088" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18180917" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0235" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Detection of extra-regional tumour recurrence with <span class="elsevierStyleSup">18</span>F-FDG-PET/CT in patients with recurrent gynaecological malignancies being considered for radical salvage surgery" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Brar" 1 => "T. May" 2 => "N. Tau" 3 => "D. Langer" 4 => "P. MacCrostie" 5 => "K. Han" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.crad.2016.12.009" "Revista" => array:6 [ "tituloSerie" => "Clin Radiol" "fecha" => "2017" "volumen" => "72" "paginaInicial" => "302" "paginaFinal" => "306" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28108013" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0240" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the post therapy surveillance of endometrial carcinoma: evaluation of 88 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.Y. Park" 1 => "E.N. Kim" 2 => "D.Y. Kim" 3 => "J.H. Kim" 4 => "Y.M. Kim" 5 => "Y.T. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1525-1438.2008.01197.x" "Revista" => array:6 [ "tituloSerie" => "Int J Gynecol Cancer" "fecha" => "2008" "volumen" => "18" "paginaInicial" => "1332" "paginaFinal" => "1338" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18298562" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0245" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "S. Pecorelli" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Gynaecol Obstet" "fecha" => "2009" "volumen" => "105" "paginaInicial" => "103" "paginaFinal" => "104" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19367689" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0250" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R. Boellaard" 1 => "M.J. O’Doherty" 2 => "W.A. Weber" 3 => "F.M. Mottaghy" 4 => "M.N. Lonsdale" 5 => "S.G. Stroobants" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-009-1297-4" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2010" "volumen" => "37" "paginaInicial" => "181" "paginaFinal" => "200" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19915839" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0255" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carcinoma endometrium: role of 18-FDG PET/CT for detection of suspected recurrence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Sharma" 1 => "R. Kumar" 2 => "H. Singh" 3 => "S. Jeph" 4 => "D.N. Sharma" 5 => "C. Bal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/RLU.0b013e31824d24fa" "Revista" => array:6 [ "tituloSerie" => "Clin Nucl Med" "fecha" => "2012" "volumen" => "37" "paginaInicial" => "649" "paginaFinal" => "655" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22691505" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0260" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleSup">18</span>F-FDG PET in the management of endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Chao" 1 => "T.C. Chang" 2 => "K.K. Ng" 3 => "S. Hsueh" 4 => "H.J. Huang" 5 => "H.H. Chou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-005-1876-y" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2006" "volumen" => "33" "paginaInicial" => "36" "paginaFinal" => "44" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16167154" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0265" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Role of <span class="elsevierStyleSup">18</span>F-FDG PET/CT in restaging and follow-up of patients with uterine sarcomas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "D. Albano" 1 => "V. Zizioli" 2 => "G. Treglia" 3 => "F. Odicino" 4 => "R. Giubbini" 5 => "F. Bertagna" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2018.04.006" "Revista" => array:2 [ "tituloSerie" => "Rev Esp Med Nucl Mol Imaging" "fecha" => "2018" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0270" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "H.H. Chung" 1 => "G.J. Cheon" 2 => "H.S. Kim" 3 => "J.W. Kim" 4 => "N.H. Park" 5 => "Y.S. Song" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-014-2775-x" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2014" "volumen" => "41" "paginaInicial" => "1793" "paginaFinal" => "1799" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24777491" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0275" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The preoperative maximum standardized uptake value measured by <span class="elsevierStyleSup">18</span>F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Walentowicz-Sadlecka" 1 => "B. Malkowski" 2 => "P. Walentowicz" 3 => "P. Sadlecki" 4 => "A. Marszalek" 5 => "T. Pietrzak" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1155/2014/234813" "Revista" => array:4 [ "tituloSerie" => "Biomed Res Int" "fecha" => "2014" "volumen" => "2014" "paginaInicial" => "234813" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0280" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The measurement of SUVmax of the primary tumor is predictive of prognosis for patients with endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "K. Nakamura" 1 => "A. Hongo" 2 => "J. Kodama" 3 => "Y. Hiramatsu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ygyno.2011.06.026" "Revista" => array:7 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "2011" "volumen" => "123" "paginaInicial" => "82" "paginaFinal" => "87" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21764107" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S157509221500090X" "estado" => "S300" "issn" => "15750922" ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0285" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.L. Antonsen" 1 => "A. Loft" 2 => "R. Fisker" 3 => "A.L. Nielsen" 4 => "E.S. Andersen" 5 => "E. Hogdall" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ygyno.2013.01.019" "Revista" => array:7 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "2013" "volumen" => "129" "paginaInicial" => "298" "paginaFinal" => "303" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23376805" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028207012289" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0290" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic significance of SUVmax (maximum standardized uptake value) measured by [18F]FDG PET/CT in endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "K. Kitajima" 1 => "M. Kita" 2 => "K. Suzuki" 3 => "M. Senda" 4 => "Y. Nakamoto" 5 => "K. Sugimura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-011-2057-9" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2012" "volumen" => "39" "paginaInicial" => "840" "paginaFinal" => "845" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22349717" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0295" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in endometrioid endometrial carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "H.H. Chung" 1 => "G.J. Cheon" 2 => "J.W. Kim" 3 => "N.H. Park" 4 => "Y.S. Song" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00259-017-3805-2" "Revista" => array:6 [ "tituloSerie" => "Eur J Nucl Med Mol Imaging" "fecha" => "2018" "volumen" => "45" "paginaInicial" => "47" "paginaFinal" => "55" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28828510" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0300" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prediction of recurrence by preoperative intratumoral FDG uptake heterogeneity in endometrioid endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.Y. Kang" 1 => "G.J. Cheon" 2 => "M. Lee" 3 => "H.S. Kim" 4 => "J.W. Kim" 5 => "N.H. Park" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.tranon.2017.01.002" "Revista" => array:6 [ "tituloSerie" => "Transl Oncol" "fecha" => "2017" "volumen" => "10" "paginaInicial" => "178" "paginaFinal" => "183" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28167243" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0305" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic value of preoperative metabolic tumor volume measured by <span class="elsevierStyleSup">18</span>F-FDG PET/CT and MRI in patients with endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.H. Chung" 1 => "I. Lee" 2 => "H.S. Kim" 3 => "J.W. Kim" 4 => "N.H. Park" 5 => "Y.S. Song" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ygyno.2013.06.021" "Revista" => array:6 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "2013" "volumen" => "130" "paginaInicial" => "446" "paginaFinal" => "451" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23791826" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0310" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic tumor volume by <span class="elsevierStyleSup">18</span>F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F.Y. Liu" 1 => "A. Chao" 2 => "C.H. Lai" 3 => "H.H. Chou" 4 => "T.C. Yen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ygyno.2012.03.021" "Revista" => array:6 [ "tituloSerie" => "Gynecol Oncol" "fecha" => "2012" "volumen" => "125" "paginaInicial" => "566" "paginaFinal" => "571" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22440787" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0315" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prognostic Value of Metabolic Activity Measured by (18)F-FDG PET/CT in Patients with Advanced Endometrial Cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.J. Kim" 1 => "J. Choi" 2 => "Y.H. Jeong" 3 => "K.H. Jo" 4 => "J.H. Lee" 5 => "A. Cho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13139-013-0228-2" "Revista" => array:6 [ "tituloSerie" => "Nucl Med Mol Imaging" "fecha" => "2013" "volumen" => "47" "paginaInicial" => "257" "paginaFinal" => "262" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24900121" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0320" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metabolic tumour volume and total lesion glycolysis, measured using preoperative <span class="elsevierStyleSup">18</span>F-FDG PET/CT, predict the recurrence of endometrial cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.H. Shim" 1 => "D.Y. Kim" 2 => "D.Y. Lee" 3 => "S.W. Lee" 4 => "J.Y. Park" 5 => "J.J. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/1471-0528.12543" "Revista" => array:7 [ "tituloSerie" => "BJOG" "fecha" => "2014" "volumen" => "121" "paginaInicial" => "1097" "paginaFinal" => "1106" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24397772" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0014256511000865" "estado" => "S300" "issn" => "00142565" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000003800000002/v1_201903020621/S2253808918300740/v1_201903020621/en/main.assets" "Apartado" => array:4 [ "identificador" => "7926" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000003800000002/v1_201903020621/S2253808918300740/v1_201903020621/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808918300740?idApp=UINPBA00004N" ]
Year/Month | Html | Total | |
---|---|---|---|
2019 March | 1 | 0 | 1 |